CureVac N.V. (NASDAQ:CVAC) saw a downside of -13.75% on Friday at $47.11 after subtracting -$7.51. The 5-day average trading volume is 464,997 shares of the company’s common stock. It has gained $58.36 in the past week and touched a new high 1 time within the past 5 days. An average of 477,669 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 607,938.
CVAC’s 1-month performance is -17.03% or -$23.40 on its low of $45.68 reached on 10/01/21. The company’s shares have touched a 52-week low of $46.12 and high of $151.80, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, CVAC has lost -32.63% or -$34.62 and has reached a new high 7 times. However, the current price is down -68.97%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
CureVac N.V. (CVAC) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.22 for the sector, meaning that investors are optimistic about the stock’s future prospects. CVAC stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 198.41. The trailing 12-month EBITDA margin is -244.22%. The firm’s gross profit as reported stood at $39.64 million against revenue of $55.83 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Return on investment over the past year is -14.20%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending December 30 this year, Analysts expected CVAC to announce -$0.61 per share in earnings in its latest quarter, but it posted -$0.38, representing a 37.70% surprise. CVAC stock balance sheet for the quarter ending December 30 shows that, with total debt at $55.28 million
Let’s look briefly at CureVac N.V. (CVAC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 18.80% to suggest the stock is trending oversold, with historical volatility in this time period at 88.83%.
The stock’s 5-day moving average is $53.65, reflecting a -19.97% or -$11.59 change from its current price. CVAC is currently trading -35.34% above its 20-day SMA, -52.59% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -15.67% and -61.73% respectively.
Stochastic %K and %D was 12.17% and 17.15% and the average true range (ATR) pointed at 3.54. The RSI (14) points at 26.71%, while the 14-day stochastic is at 3.91% with the period’s ATR at 3.56. The stock’s 9-day MACD Oscillator is pointing at -2.79 and -3.27 on the 14-day charts.
In the most recent analyst report for CureVac N.V. (NASDAQ: CVAC), BofA Securities downgraded it to a Neutral rating. They previously had a Buy rating on the stock.